MedPath

Evaluation of biomarkers of acute kidney injury (AKI) in the ICU population.

Not Applicable
Conditions
acute kidney injury
Registration Number
JPRN-UMIN000004503
Lead Sponsor
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Department of Medicine and Clinical Science
Brief Summary

The urinary levels of prostaglandin E2 (PGE2), PGI2 metabolite (2,3-dinor-6-OXO-PGF1 alfa), thromboxane A2 (TXA2) metabolite (11-dehydro-TXB2) were determined. Of the 93 patients, 24 developed AKI (AKIN criteria). Overall, the ratio of the level of serum Cr on Day 1 after ICU admission to that observed at baseline positively correlated with the urinary 2,3-dinor-6-OXO-PGF1alfa /Cr (r = 0.57, p < 0.0001) and 11-dehydro-TXB2/Cr (r = 0.47, p < 0.0001) ratios. In 16 cases of de novo AKI, the urinary 2,3-dinor-6-OXO-PGF1 alfa /Cr and 11-dehydro-TXB2/Cr values were significantly elevated compared with that observed in the non-AKI group. The urinary 2,3-dinor-6-OXO-PGF1 alfa /Cr ratio exhibited the best diagnostic and predictive performance among the prostanoid metabolites according to the receiver operating characteristic (ROC) analysis [ROC-area under the curve (AUC): 0.75

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
200
Inclusion Criteria

Not provided

Exclusion Criteria

The patients already performing renal replacement therapy by end-stage renal disease. The patients that informed consent was obtained. Minority (under 20 years old) The patients that was discharged ICU after entering ICU for 24 hours.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath